StockNews.AI
HIMS
StockNews.AI
56 days

Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS

1. DJS Law Group is investigating HIMS for potential securities law violations. 2. Novo Nordisk ended its collaboration with HIMS over illegal compounding practices. 3. HIMS shares plummeted 31.7% due to the negative press and investor panic. 4. Concerns about HIMS's marketing and patient safety threaten investor confidence. 5. Investors are encouraged to join the investigation for potential claims.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The termination of a significant partnership and allegations of illegal practices severely undermine HIMS's market position, reminiscent of other firms facing regulatory scrutiny that saw sharp declines in stock prices, such as Theranos.

How important is it?

The investigation and associated allegations pose a direct threat to HIMS's operations and investor perceptions, making it critical for market performance.

Why Short Term?

Immediate investor reactions indicate short-term price volatility, similar to cases where swift actions lead to rapid share price adjustments, particularly in the wake of legal troubles.

Related Companies

NVDATDOCCNC
, /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Novo Nordisk issued a press release on June 23, 2025, announced that it was terminating its "collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing." According to the press release, "the FDA resolved the Wegovy® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy® through NovoCare® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk." Based on this, shares of Hims & Hers fell by 31.7% in afternoon trading on June 23, 2025. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected]  SOURCE DJS Law Group LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News